MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 8, Pages 2831
Publisher
MDPI AG
Online
2020-04-21
DOI
10.3390/ijms21082831
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- GENETICS IN ENDOCRINOLOGY: Somatic and germline mutations in the pathogenesis of pituitary adenomas
- (2019) Silvia Vandeva et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Pituitary Adenomas and Invasiveness from Anatomo-Surgical, Radiological, and Histological Perspectives: A Systematic Literature Review
- (2019) Simona Serioli et al. Cancers
- The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma
- (2018) Anne M. Mills et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- The 2017 WHO classification of pituitary adenoma: overview and comments
- (2018) Naoko Inoshita et al. Brain Tumor Pathology
- New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors
- (2018) Hiroshi Nishioka et al. Brain Tumor Pathology
- Reduced Expression of Mismatch Repair Genes MSH6/MSH2 Directly Promotes Pituitary Tumor Growth via the ATR–Chk1 Pathway
- (2018) Shinsuke Uraki et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- CLINICAL AND PATHOLOGICAL ASPECTS OF SILENT PITUITARY ADENOMAS
- (2018) Juliana Drummond et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy
- (2018) Peng-fei Wang et al. JOURNAL OF NEURO-ONCOLOGY
- Marked response of a hypermutated adrenocorticotropic hormone-secreting pituitary carcinoma to ipilimumab and nivolumab
- (2018) Andrew L Lin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- DNA methylation of Tumour Suppressor Genes in Pituitary Neuroendocrine Tumours
- (2018) A García-Martínez et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal
- (2017) S L Asa et al. ENDOCRINE-RELATED CANCER
- Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in a Nationwide LS Cohort
- (2017) Daniel Bengtsson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Aggressive Behavior in Silent Subtype III Pituitary Adenomas May Depend on Suppression of Local Immune Response: A Whole Transcriptome Analysis
- (2017) Timothy E. Richardson et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
- (2016) Matthew W Rosenbaum et al. MODERN PATHOLOGY
- Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas
- (2016) Ozgur Mete et al. MODERN PATHOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
- (2016) Yu Mei et al. Oncotarget
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) K. Ota et al. CLINICAL CANCER RESEARCH
- The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas
- (2015) Hiroshi Nishioka et al. ENDOCRINE PATHOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Correlation Between Histological Subtypes and MRI Findings in Clinically Nonfunctioning Pituitary Adenomas
- (2012) Hiroshi Nishioka et al. ENDOCRINE PATHOLOGY
- Mismatch repair deficient colorectal cancer in the era of personalized treatment
- (2010) Madeleine Hewish et al. Nature Reviews Clinical Oncology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search